Sunitinib Malate (SU011248) — Competitive Intelligence Brief

Sunitinib Malate (SU011248) (Sunitinib Malate (SU011248)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor. Area: Oncology.

marketed Multi-targeted tyrosine kinase inhibitor VEGFR, PDGFR, KIT, FLT3 Oncology Small molecule

Target snapshot

Sunitinib Malate (SU011248) (Sunitinib Malate (SU011248)) — H. Lee Moffitt Cancer Center and Research Institute. Sunitinib is a multi-targeted tyrosine kinase inhibitor that blocks growth factor receptors (VEGFR, PDGFR, KIT, FLT3) to inhibit tumor angiogenesis and cell proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sunitinib Malate (SU011248) TARGET	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Sunitinib (Sutent)	Sunitinib (Sutent)	Sponsor GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET
Lenvatinib, tislelizumab, gemcitabine and cisplatin	Lenvatinib, tislelizumab, gemcitabine and cisplatin	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination	FGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
2. Exelixis · 2 drugs in this class
3. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Cancer Institute, Naples · 1 drug in this class
6. Sponsor GmbH · 1 drug in this class
7. Sun Yat-sen University · 1 drug in this class
8. TransThera Sciences (Nanjing), Inc. · 1 drug in this class
9. Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class